Refractory Follicular Lymphoma Clinical Trials

46 clinical trials for Refractory Follicular Lymphoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma — RECRUITING · PHASE2
• Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial — RECRUITING · PHASE2
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy — RECRUITING · PHASE2
• B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies — RECRUITING · PHASE1
• Q702 for the Treatment of Patients With Hematologic Malignancies — RECRUITING · PHASE1
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies — TERMINATED · PHASE1
• Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas — COMPLETED · PHASE2
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies — TERMINATED · PHASE2
• Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment — ACTIVE_NOT_RECRUITING · PHASE1
• Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation — WITHDRAWN · PHASE2
• Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment — ACTIVE_NOT_RECRUITING · PHASE1
• Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. — ACTIVE_NOT_RECRUITING · PHASE1
• Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies — TERMINATED · PHASE1
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma — TERMINATED · PHASE2
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma — COMPLETED · PHASE1
• Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma — COMPLETED · PHASE1
• TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma — COMPLETED · PHASE1
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant — COMPLETED · PHASE2
• Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma — TERMINATED · PHASE2
• Zandelisib + Tazemetostat in R/R Follicular Lymphoma — WITHDRAWN · PHASE1
• Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma — WITHDRAWN · PHASE1
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma — COMPLETED · PHASE2
• Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma — WITHDRAWN · PHASE1
• Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma — WITHDRAWN · PHASE1
• Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma — COMPLETED · PHASE1
• CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma — WITHDRAWN · PHASE1
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer — COMPLETED · PHASE2
• Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas — COMPLETED · PHASE1

Refine this search